Ken Griffin Chroma Dex Corp. Call Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$3.25 - $7.72 $44,850 - $106,536	13,800 Added 51.88%	40,400 $214,000
Q3 2024 Nov 14, 2024	BUY	$2.51 - $3.8 $21,836 - $33,060	8,700 Added 48.6%	26,600 $97,000
Q2 2024 Aug 14, 2024	SELL	$2.44 - $4.32 $19,276 - $34,128	-7,900 Reduced 30.62%	17,900 $48,000
Q1 2024 May 15, 2024	BUY	$1.36 - $3.84 $31,280 - $88,320	23,000 Added 821.43%	25,800 $89,000
Q4 2023 Feb 14, 2024	BUY	$1.28 - $1.6 $1,408 - $1,760	1,100 Added 64.71%	2,800 $4,000
Q3 2023 Nov 14, 2023	SELL	$1.36 - $1.77 $7,208 - $9,381	-5,300 Reduced 75.71%	1,700 $2,000
Q2 2023 Aug 14, 2023	SELL	$1.31 - $1.79 $52,793 - $72,137	-40,300 Reduced 85.2%	7,000 $10,000
Q1 2023 May 15, 2023	SELL	$1.48 - $2.19 $63,640 - $94,170	-43,000 Reduced 47.62%	47,300 $72,000
Q4 2022 Feb 14, 2023	BUY	$1.25 - $1.94 $64,875 - $100,686	51,900 Added 135.16%	90,300 $151,000
Q3 2022 Nov 14, 2022	BUY	$1.19 - $2.06 $3,451 - $5,974	2,900 Added 8.17%	38,400 $47,000

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $519M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.